- Main /
- Company /
- 591-alumis

IPO
ALMS.NASDAQ
Past
Alumis
Pharmaceuticals
Company websiteTicker
ALMS.NASDAQ
Market
us
Foundation year
2021
IPO date
6/13/2024
About
Alumis is dedicated to significantly enhancing patient lives by transitioning from broad immunosuppression to precise therapies. The name "Alumis" reflects this commitment, deriving from the French word "allumer" meaning to illuminate, and "immunis," the Latin term for the immune system.
Underwriters
Morgan Stanley, Leerink, Cantor, Guggenheim Securities